Media Details

  • Home
  • Media
  • Details
  2020-09-25 16:27:26

Ho Wah Genting Berhad’s JV partner EBI collaborates with Dr. Roderick to conduct a multi centre clinical study for COVID-19 prevention

KUALA LUMPUR, 25 SEPTEMBER 2020Ho Wah Genting Berhad’s (“HWGB” or the “Company”) (Bursa Stock Code:9601) wholly-owned subsidiary, HWGB Biotech Sdn Bhd’s (“HWGB Biotech”) [formerly known as HWG Consortium Sdn Bhd] joint venture partner, US-based E-MO Biology Inc. (“EBI”), is in collaboration with Roderick A. Comunale II MD Inc (“Roderick Inc”) to conduct a multi centre clinical study for covid-19 prevention.
Dr. Roderick A. Comunale (“Dr. Roderick”) is currently conducting a multi-centre clinical study entitled “Inactivated Polio Vaccine (“IPV”) in prevention of COVID-19 in high risk population in a Phase IV study", to study the effects of Inactivate Polio Vaccine-IPV.
An appropriate number of volunteers, covering all age groups will be recruited after screening their medical records to ensure their eligibility to participate in the clinical study.
EBI has also submitted the finalized research protocol for approval by the United States Food and Drug Administration (“FDA”) on the use of IPV for the potential new indication, with Dr. Roderick as the principal investigator for the research protocol.
To support the research, EBI is also collaborating with America Diagnostic & Genescan Diagnostics Inc to develop a series of immunology assays needed to conduct the clinical study.
Ho Wah Genting Berhad (“HWGB” or the “Company”) is principally engaged in investment holdings and the provision of management services to its subsidiaries. The Company had on 30 June 2020 diversified its existing businesses to include healthcare related industry which mainly involved in Health Supplement, Biotechnology and Health Technology. In addition, the Company and its subsidiaries (“HWGB Group” or the “Group”) are also engage in the businesses of Investment holdings; manufacturing of wire and cable and moulded power supply cord sets and cable assemblies for electrical and electronic devices and equipment; trading of wire and cable; and travel agent and tour related services.

For more information about HWGB Biotech, please visit and/or 
Please also feel free to subscribe to our newsletter online to get latest exciting developments of our new ventures. Click on to subscribe.
E-MO Biology Inc (“EBI”) was incorporated in the state of California in the United States of America on 24 May 2020. It is principally involved in conducting biology research and development activities and is the sponsor of a study which indicates booster polio vaccine to reduce Covid-19 SARS-COV-2 infection and severity.
EBI is founded by Prof. Xie QiYi, who serves as its Director and Chief Executive Officer. He has over 30 years of experiences in areas of public health and infection disease control. He was also involved in the development of medical and diagnostic devices, with focus on quality, regulatory and clinical affairs for quality systems.